Vanguard Group Inc. Acquires 115,367 Shares of Liquidia Co. (NASDAQ:LQDA)

Vanguard Group Inc. raised its holdings in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,557,296 shares of the company's stock after acquiring an additional 115,367 shares during the quarter. Vanguard Group Inc. owned approximately 4.20% of Liquidia worth $41,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its position in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after buying an additional 230,820 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock valued at $2,354,000 after acquiring an additional 210,753 shares during the period. Barclays PLC increased its holdings in Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company's stock worth $999,000 after acquiring an additional 72,591 shares in the last quarter. XTX Topco Ltd purchased a new position in Liquidia during the third quarter valued at approximately $323,000. Finally, Wellington Management Group LLP boosted its position in shares of Liquidia by 12.5% in the third quarter. Wellington Management Group LLP now owns 179,923 shares of the company's stock worth $1,799,000 after purchasing an additional 19,932 shares during the period. Institutional investors own 64.54% of the company's stock.

Liquidia Trading Down 0.7 %

Shares of LQDA stock traded down $0.09 during trading hours on Thursday, reaching $13.59. 114,354 shares of the stock were exchanged, compared to its average volume of 968,429. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -8.32 and a beta of 0.23. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The company's 50-day moving average price is $14.75 and its 200-day moving average price is $12.73.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The business had revenue of $2.92 million for the quarter, compared to analysts' expectations of $4.60 million. On average, sell-side analysts expect that Liquidia Co. will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LQDA. Needham & Company LLC restated a "buy" rating and set a $25.00 target price on shares of Liquidia in a research note on Thursday, April 10th. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. Scotiabank reissued an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. Finally, Wells Fargo & Company began coverage on shares of Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $26.63.

Insiders Place Their Bets

In related news, CFO Michael Kaseta sold 8,283 shares of the firm's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $112,400.31. Following the transaction, the chief financial officer now owns 396,315 shares of the company's stock, valued at $5,377,994.55. This trade represents a 2.05 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jason Adair sold 1,856 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the sale, the insider now directly owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. This trade represents a 1.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,123 shares of company stock worth $448,366 over the last quarter. Company insiders own 30.10% of the company's stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).